Back to Search
Start Over
Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy
- Source :
- Journal of Pharmacology and Experimental Therapeutics. 366:158-168
- Publication Year :
- 2018
- Publisher :
- American Society for Pharmacology & Experimental Therapeutics (ASPET), 2018.
-
Abstract
- B-type natriuretic peptide (BNP) is widely used as a diagnostic marker of systolic dysfunction. We previously conducted a clinical study in which anthracycline or nonanthracycline chemotherapy did not cause systolic dysfunction in cancer patients; however, some patients showed asymptomatic alterations in diastolic relaxation, whereas others showed persistent elevations of BNP, measured as prohormone BNP amino-terminal fragment. Here we describe post hoc pharmacologic analyses showing that: 1) impaired relaxation and persistent elevations of BNP were mutually exclusive manifestations of diastolic dysfunction; 2) in some patients, BNP elevations were induced by an early compromise of myocardial relaxation; 3) BNP elevations then halted further deterioration of relaxation in a concentration-dependent manner; and 4) high BNP increased heart rate (HR). BNP elevations therefore caused positive lusitropy and chronotropism, which might be explained by activation of natriuretic receptor-associated guanylyl cyclase and production of cGMP in ventricular myocytes and sinoatrial node, respectively. BNP levels also influenced responses to a lusitropic drug, ranolazine, that was given to treat diastolic dysfunction. For patients with impaired relaxation and normal or only transiently high levels of BNP, ranolazine improved myocardial relaxation without inducing chronotropic effects. For patients in whom relaxation abnormalities were corrected by persistently high BNP levels, ranolazine substituted for BNP and decreased HR by diminishing BNP levels. These findings describe a pharmacologic scenario in which cancer drugs cause an early diastolic dysfunction that in some patients is both heralded and modulated by BNP elevations. Patients showing BNP elevations should therefore receive the adequate pharmacologic treatment of correcting diastolic dysfunction and tachycardia.
- Subjects :
- Adult
Male
Chronotropic
Tachycardia
medicine.medical_specialty
Lusitropy
Adolescent
medicine.drug_class
Muscle Relaxation
Diastole
Ranolazine
Antineoplastic Agents
030204 cardiovascular system & hematology
Asymptomatic
Young Adult
03 medical and health sciences
0302 clinical medicine
Heart Rate
Internal medicine
Natriuretic Peptide, Brain
medicine
Natriuretic peptide
Humans
Anthracyclines
cardiovascular diseases
Aged
Pharmacology
business.industry
Sinoatrial node
Heart
Middle Aged
Myocardial Contraction
medicine.anatomical_structure
030220 oncology & carcinogenesis
cardiovascular system
Cardiology
Molecular Medicine
Female
medicine.symptom
business
human activities
hormones, hormone substitutes, and hormone antagonists
circulatory and respiratory physiology
medicine.drug
Subjects
Details
- ISSN :
- 15210103 and 00223565
- Volume :
- 366
- Database :
- OpenAIRE
- Journal :
- Journal of Pharmacology and Experimental Therapeutics
- Accession number :
- edsair.doi.dedup.....0280e760418403e7f925ff1e1a5a3be5
- Full Text :
- https://doi.org/10.1124/jpet.118.249235